<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850511</url>
  </required_header>
  <id_info>
    <org_study_id>12-001362</org_study_id>
    <nct_id>NCT01850511</nct_id>
  </id_info>
  <brief_title>The Effect of Nasal Hair on Nasal Obstruction</brief_title>
  <official_title>The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasal obstruction is a common complaint prompting presentation to an otolaryngologist. Many
      studies have been performed quantifying and describing the impact of a number of factors on
      symptoms of nasal obstruction, including anatomical, neoplastic, infectious, and inflammatory
      causes. Despite this scrutiny, no attention has been paid to the nasal vibrissae as a
      potential anatomical contributor to nasal obstruction. The proposed study intends to
      elucidate that contribution, if any exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal airflow/pressure</measure>
    <time_frame>Participants will undergo assessment over a 30 minute period, no follow-up</time_frame>
    <description>Objective measures include airflow and pressure as assessed by Rhinomanometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Nasal Obstruction</measure>
    <time_frame>Participants will undergo assessment over a 30 minute period, no follow-up</time_frame>
    <description>Subjective measures will be assessed via the modified version of the NOSE outcome instrument-a validated test of subjective nasal obstruction</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nasal Obstruction</condition>
  <arm_group>
    <arm_group_label>Vibrissae trimming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vibrissae trimming</intervention_name>
    <description>Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.</description>
    <arm_group_label>Vibrissae trimming</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Application of oxymetazoline</intervention_name>
    <description>Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.</description>
    <arm_group_label>Vibrissae trimming</arm_group_label>
    <other_name>Afrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of nasal vibrissae

          -  Able to tolerate rhinomanometry

        Exclusion Criteria:

          -  Anatomical or other obvious cause of obstruction

          -  Claustrophobia with rhinomanometry mask
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Hamilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ozturk AB, Damadoglu E, Karakaya G, Kalyoncu AF. Does nasal hair (vibrissae) density affect the risk of developing asthma in patients with seasonal rhinitis? Int Arch Allergy Immunol. 2011;156(1):75-80. doi: 10.1159/000321912. Epub 2011 Mar 30.</citation>
    <PMID>21447962</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>David (Dave) G. Stoddard, Jr., M.D.</investigator_full_name>
    <investigator_title>Resident Physician, Department of Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>Nasal obstruction</keyword>
  <keyword>Vibrissae</keyword>
  <keyword>Nasal hair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

